Leora Horn
利奥拉·霍恩
MD, MSc
Professor of Medicine, Director of Thoracic Oncology医学教授，胸部肿瘤学主任
👥Biography 个人简介
Dr. Leora Horn is a leading thoracic oncologist at Vanderbilt whose landmark work on the KEYNOTE-024 trial established pembrolizumab as first-line standard of care for PD-L1-high NSCLC. She is internationally recognized for biomarker-driven immunotherapy research.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KEYNOTE-024 & PD-L1 Biomarker Research
Key contributor to KEYNOTE-024, demonstrating pembrolizumab superiority over chemotherapy in PD-L1 ≥50% NSCLC, reshaping first-line treatment and validating PD-L1 as a predictive biomarker.
Representative Works 代表性著作
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (KEYNOTE-024)
New England Journal of Medicine (2016)
Pivotal RCT establishing pembrolizumab as first-line therapy for PD-L1 ≥50% NSCLC, transforming the treatment paradigm.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 利奥拉·霍恩 的研究动态
Follow Leora Horn's research updates
留下邮箱，当我们发布与 Leora Horn（Vanderbilt University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment